OCULAR THERAPEUTIX, INC Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
OCULAR THERAPEUTIX, INC (OCUL) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$167.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$78.76M.
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$88.61M.
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$64.65M.
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$69.42M.
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$265.94M.
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$193.51M.
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$80.74M.
- OCULAR THERAPEUTIX, INC net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$71.04M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$78.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$167.38M 10-Q · filed 2026-08-03 | -$232.03M derived: sum of 3 quarters · filed 2026-08-03 | -$301.45M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | -$88.61M 10-Q · filed 2026-05-05 | -$153.27M derived: sum of 2 quarters · filed 2026-05-05 | -$222.68M derived: sum of 3 quarters · filed 2026-05-05 | -$290.50M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | -$64.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$134.07M derived: sum of 2 quarters · filed 2026-02-05 | -$201.89M derived: sum of 3 quarters · filed 2026-08-03 | -$265.94M 10-K · filed 2026-02-05 | ||||
| 2025-09-30 | -$69.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$137.23M derived: sum of 2 quarters · filed 2026-08-03 | -$201.28M 10-Q · filed 2025-11-04 | -$249.67M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | -$67.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$131.87M 10-Q · filed 2026-08-03 | -$180.25M derived: sum of 3 quarters · filed 2026-08-03 | -$216.75M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | -$64.05M 10-Q · filed 2026-05-05 | -$112.44M derived: sum of 2 quarters · filed 2026-05-05 | -$148.93M derived: sum of 3 quarters · filed 2026-05-05 | -$192.71M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$48.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$84.88M derived: sum of 2 quarters · filed 2026-02-05 | -$128.66M derived: sum of 3 quarters · filed 2026-02-05 | -$193.51M 10-K · filed 2026-02-05 | ||||
| 2024-09-30 | -$36.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$80.27M derived: sum of 2 quarters · filed 2025-11-04 | -$145.12M 10-Q · filed 2025-11-04 | -$174.34M derived: sum of 4 quarters · filed 2026-02-05 | ||||
| 2024-06-30 | -$43.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$108.63M 10-Q · filed 2025-08-05 | -$137.84M derived: sum of 3 quarters · filed 2026-02-05 | -$138.36M derived: sum of 4 quarters · filed 2026-02-05 | ||||
| 2024-03-31 | -$64.85M 10-Q · filed 2025-05-05 | -$94.07M derived: sum of 2 quarters · filed 2026-02-05 | -$94.58M derived: sum of 3 quarters · filed 2026-02-05 | -$115.27M derived: sum of 4 quarters · filed 2026-02-05 | ||||
| 2023-12-31 | -$29.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$29.74M derived: sum of 2 quarters · filed 2026-02-05 | -$50.42M derived: sum of 3 quarters · filed 2026-02-05 | -$80.74M 10-K · filed 2026-02-05 | ||||
| 2023-09-30 | -$516.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$21.20M derived: sum of 2 quarters · filed 2024-11-14 | -$51.52M 10-Q · filed 2024-11-14 | -$67.06M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | -$20.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$51.00M 10-Q · filed 2024-08-07 | -$66.54M derived: sum of 3 quarters · filed 2025-03-03 | -$90.73M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | -$30.32M 10-Q · filed 2024-05-07 | -$45.86M derived: sum of 2 quarters · filed 2025-03-03 | -$70.05M derived: sum of 3 quarters · filed 2025-03-03 | -$88.81M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | -$15.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$39.73M derived: sum of 2 quarters · filed 2025-03-03 | -$58.50M derived: sum of 3 quarters · filed 2025-03-03 | -$71.04M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | -$24.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$42.95M derived: sum of 2 quarters · filed 2023-11-07 | -$55.50M 10-Q · filed 2023-11-07 | -$59.35M derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2022-06-30 | -$18.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$31.31M 10-Q · filed 2023-08-07 | -$35.16M derived: sum of 3 quarters · filed 2024-03-11 | -$32.50M derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2022-03-31 | -$12.54M 10-Q · filed 2023-05-08 | -$16.39M derived: sum of 2 quarters · filed 2024-03-11 | -$13.73M derived: sum of 3 quarters · filed 2024-03-11 | -$22.22M derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2021-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$1.19M derived: sum of 2 quarters · filed 2024-03-11 | -$9.67M derived: sum of 3 quarters · filed 2024-03-11 | -$6.55M 10-K · filed 2024-03-11 | ||||
| 2021-09-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$5.82M derived: sum of 2 quarters · filed 2022-11-07 | -$2.70M 10-Q · filed 2022-11-07 | -$88.31M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-06-30 | -$8.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$5.36M 10-Q · filed 2022-08-08 | -$90.97M derived: sum of 3 quarters · filed 2023-03-06 | -$102.92M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-03-31 | $3.12M 10-Q · filed 2022-05-09 | -$82.49M derived: sum of 2 quarters · filed 2023-03-06 | -$94.44M derived: sum of 3 quarters · filed 2023-03-06 | -$131.00M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2020-12-31 | -$85.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$97.56M derived: sum of 2 quarters · filed 2023-03-06 | -$134.12M derived: sum of 3 quarters · filed 2023-03-06 | -$155.64M 10-K · filed 2023-03-06 | ||||
| 2020-09-30 | -$11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$48.51M derived: sum of 2 quarters · filed 2021-11-08 | -$70.02M 10-Q · filed 2021-11-08 | -$96.04M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | -$36.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$58.08M 10-Q · filed 2021-08-09 | -$84.10M derived: sum of 3 quarters · filed 2022-02-28 | -$102.88M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | -$21.51M 10-Q · filed 2021-05-05 | -$47.53M derived: sum of 2 quarters · filed 2022-02-28 | -$66.31M derived: sum of 3 quarters · filed 2022-02-28 | -$90.76M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | -$26.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$44.80M derived: sum of 2 quarters · filed 2022-02-28 | -$69.25M derived: sum of 3 quarters · filed 2022-02-28 | -$86.37M 10-K · filed 2022-02-28 | $86.37M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | -$18.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$43.23M derived: sum of 2 quarters · filed 2020-11-05 | -$60.35M 10-Q · filed 2020-11-05 | $60.35M 10-Q · filed 2019-11-12 | -$42.96M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | -$24.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$41.58M 10-Q · filed 2020-08-07 | $41.58M 10-Q · filed 2019-08-07 | -$24.18M derived: sum of 3 quarters · filed 2020-08-07 | -$9.17M derived: sum of 4 quarters · filed 2020-08-07 | |||
| 2019-03-31 | -$17.12M 10-Q · filed 2020-05-08 | $17.12M 10-Q · filed 2019-05-10 | $275.00K derived: sum of 2 quarters · filed 2020-05-08 | $15.29M derived: sum of 3 quarters · filed 2020-05-08 | $29.09M derived: sum of 4 quarters · filed 2020-05-08 | |||
| 2018-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $32.41M derived: sum of 2 quarters · filed 2020-03-12 | $46.21M derived: sum of 3 quarters · filed 2020-03-12 | $59.98M 10-K · filed 2020-03-12 | -$59.98M 10-K · filed 2019-03-07 | |||
| 2018-09-30 | $15.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $28.81M derived: sum of 2 quarters · filed 2019-11-12 | $42.58M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $13.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $27.57M 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | $13.77M 10-Q · filed 2019-05-10 | |||||||
| 2017-12-31 | $63.39M 10-K · filed 2020-03-12 | -$63.39M 10-K · filed 2019-03-07 | ||||||
| 2016-12-31 | -$44.70M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |